Taris, AstraZeneca partner for bladder cancer

Taris Biomedical Inc. (Lexington, Mass.) and AstraZeneca plc (LSE:AZN; NYSE:AZN) partnered to evaluate bladder cancer therapies using Taris' bladder delivery technology with undisclosed genetically targeted compounds from AstraZeneca. The pharma will have an exclusive option to license products resulting from the deal. Taris' technology is inserted into the bladder by a physician using standard procedures and without general anesthesia. The system provides continuous local delivery to the bladder for days to weeks. The companies are not disclosing financial terms. ...